Anonymous
Guest
Anonymous
Guest
Some of you may be interested in a news release from "MarketWatch London" on Thursday, September 10, 2009
MarketWatch Pulse
LONDON -- Societe Generale cut its rating on U.K. drugs company GlaxoSmithKline to sell from hold, citing the looming threat of generics to its best-selling respiratory distress drug Advair. The broker told clients that the market is underestimating the likelihood of a fully substitutable generic in the U.S. from 2011.
Also I just order Seroflo from Canada yo replace the Advair I have been taking. Advair just went to $200.11 with insurance for me.
MarketWatch Pulse
LONDON -- Societe Generale cut its rating on U.K. drugs company GlaxoSmithKline to sell from hold, citing the looming threat of generics to its best-selling respiratory distress drug Advair. The broker told clients that the market is underestimating the likelihood of a fully substitutable generic in the U.S. from 2011.
Also I just order Seroflo from Canada yo replace the Advair I have been taking. Advair just went to $200.11 with insurance for me.